NCT02419456View on ClinicalTrials.gov

Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
HIV Infections
Interventions
DRUG

MK-2048A IVR (Low Dose)

Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.

DRUG

MK-2048A IVR (Original Dose)

Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.

Trial Locations (1)

94143

Bridge HIV CRS, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02419456 - Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048 | Biotech Hunter | Biotech Hunter